Articles On Resapp Health (ASX:RAP)

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

The ResApp Health Ltd (ASX: RAP) share price is in the green today as investors digest the latest news on Pfizer’s proposed takeover bid. Shares in the ASX healthcare company are up 0.98%, trading at 21 cents at the time of writing after s...

Global biopharmaceutical giant Pfizer will progress with its $180 million takeover of Brisbane-based telehealth company ResApp Health (ASX: RAP) after the target’s shareholders voted in favour of the deal yesterday. As detailed by ResApp,...

It’s no secret that Australia is home to some of the fastest-growing health app companies in the world. Our technology unicorns have been empowering individuals to take control of their health journeys with the ease of tailored experience a...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX Powerplays. Morgans takes conservative app...

Pfizer has significantly raised its offer for Australian digital health company ResApp Health (ASX:RAP) to a price that reflects the recent findings of an independent report.

The ASX 200 is down, the XEC surged late, up 1.5%  Tech stocks rise, Cons discretionary and energy dragging US Futures flat, Chinese markets higher on Pelosi goes to Taipei day   Ahead of the close here in Sydney, US Futures connected to...

The ResApp Health Ltd (ASX: RAP) share price is leaping on news Pfizer has upped its bid for the company. The biopharmaceutical giant has agreed to acquire the Brisbane-based health technology company for 20.8 cents per share. That’s up...

Mobile healthcare company ResApp Health (RAP) used the June quarter to enter new customer agreements and research activities In April, ResApp signed a one-year agreement with the Dartford and Gravesham National Health Service Trust to use...

Australian digital health company ResApp Health (ASX:RAP) is urging shareholders to support Pfizer's acquisition of the company after the competition regulator confirmed it will not review the proposal.

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Benchmark up circa 1%, small caps surge 1.5% Coal miners eclipsed by Whitehaven record profits Kincora Copper finds so much more copper The small cap S&P/ASX Emerging Companies (XEC) index and the benchmark S&P/ASX 200 (XJO) index...

The takeover action evident at the top end of town is trickling down to the small and mid cap sectors, as mainly foreign marauders avail of the undervalued morsels on offer. In theory, the end of cheap money should have crimped takeover act...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in ASX health stocks. ASX health stocks get much needed July rally aft...

Botanix’s FDA submission gets accelerated Release extends contract with Medgate to use the ResAppDx platform Cyclopharm’s Technegas is used ahead of competitor products in Covid-19 diagnosis Clinical dermatology company, Botanix Pharma (A...

ResApp Health (RAP) agrees to a 12-month extension to its initial one-year commercial licence agreement with Medgate The agreement is to use ResApp’s smartphone-based acute respiratory diagnostic test ResAppDx on Medgate’s telehealth platf...

Digital health company ResApp Health (ASX:RAP) has agreed to a 12-month extension to its commercial licence agreement with Medgate.

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

ShareCafeEvening Report: 6 July, 2022 by Lauren Evans   Australian shares spent the afternoon in the red as commodity prices plunged on recession fears. The energy sector tumbled 5.8 per cent, with materials down 5 per cent. Real estate was...

Highlights: ASX200 loses 0.52%, as commodity prices have likely pressurised materials and energy stocks. Mining stocks FMG and RIO closed lower, while banking stocks CBA and NAB ended on positive note on ASX today. Information technol...

Highlights ResApp Health receives the US Food and Drug Administration (FDA) clearance for its SleepCheckRx mobile application SleepCheckRx is a sleep test that analyses the risk of moderate to severe obstructive sleep apnoea in adults...

ResApp gets clearance from the US FDA Immutep is granted patent in Japan Paradigm Biopharma to commence Phase 3 trial ResApp Health (ASX:RAP) announced that SleepCheckRx has received 510(k) clearance as a prescription-only Software-as-a-M...

ShareCafeLunch Report: 6 July, 2022 by Melissa Darmawan   The Australian sharemarket has been choppy this morning, trading as low as 0.5 per cent before rebounding to a gain of 0.2 per cent to then fall again. Information technology shares...

ResApp (RAP) receives 510(k) clearance from the US Food and Drug Administration (FDA) for its at-home sleep test, SleepCheckRx The test is listed as a prescription-only software-as-a-medical device and gaining FDA clearance will enable the...

Literally every sector had a red month, but mining was the worst PayGroup gets surprise $120m takeover offer from US unicorn Deel Tempest Minerals signed JV to explore near the Karara Magnetite Iron mine June was a month of global econom...

ResApp has received an acquisition deal by Pfizer Stockhead reaches out to ResApp’s CEO A list of current ASX stocks with live takeover offers Australia’s global reputation as a fertile ground for innovative companies continues to attract...

Trajan announces SPP to raise up to $5 million after institutional placement raised $29.7 million ResApp CEO and managing director Tony Keating to present at Gold Coast Investment Showcase today Italian authorities approve key Alterity Th...

Avita Medical makes spray on skin for burns and soft tissue injuries HITIQ’s concussion tech is popular for athletes and sports teams PainChek’s smartphone app can tell if babies or older Aussies are in pain There’s a plethora of biotech...

ResApp Health’s (ASX: RAP) shares sank 30% this week after the company announced less than impressive study results on its COVID-19 cough detection app, which has resulted in $53 million being immediately erased from Pfizer’s proposed takeo...

Highlights ASX 200 gained upward momentum after 7 days of losses as RBA wiped off recession fears. Australian mining giants were relieved as iron ore prices recovered some losses today. Top gainers were energy and financial sectors wh...

ShareCafeEvening Report: 21 June, 2022 by Melissa Darmawan   Australian shares snapped a seven-day losing streak led by resource and financial stocks amid the US futures pointing to a rise as Wall Street looks to resume trade after a long w...

Emerging Companies (XEC) index rises on Tuesday, up over 1.2% ASX 200 same, but a wee bit more Lode Resources rises sharply on more than just a sliver of silver   Everything’s higher on Tuesday. Not by a heap, but enough to cancel the co...

In afternoon, the S&P/ASX 200 Index (ASX: XJO) is back on form and on course to record a strong gain. At the time of writing, the benchmark index is up 1.5% to 6,531.6 points. Four ASX shares that have failed to follow the market’s...

ShareCafeLunch Report: 21 June, 2022 by Melissa Darmawan   The Australian sharemarket is set to snap a seven-day losing streak as investors were relieved that RBA governor Philip Lowe doesn’t see a local recession coming. At noon, the S&amp...

21 Jun 2022 - A snapshot of the stocks on the move, featuring ResApp (ASX:RAP), Radiopharm Theranostics (ASX:RAD), and Reece Pharmaceuticals (ASX:RCE).

ResApp Health (RAP) has plunged into the red after inadequate test results for its COVID-19 detection app shaved $53 million off of a takeover bid from Pfizer An independent confirmation study for RAP’s smartphone-based COVID-19 identifica...

ResApp’s independent study of cough app falls short Recce Pharma completes Cohort 6 dosage in Phase 1 trial Proteomics secures exclusive biomakers license Smartphone-based respiratory diagnostic maker, ResApp Health (ASX:RAP), plunged by...

The ResApp Health Ltd (ASX: RAP) share price has returned from its trading halt and taken a tumble. In morning trade, the digital health company’s shares are down 29% to 12.5 cents. Why is the ResApp share price crashing? Last week, as w...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Emerging Companies (XEC) index dives 2.6% Benchmark ASX200 down 0.6% Culpeo Minerals meets copper, shares up 70%   Aussie small caps have copped a commodities shellacking to start the week as materials, metals and energy stocks bear the...

ShareCafeWebinar Recap – RAP, WBE & KNO Catch up on the full webinar presentations from Resapp (ASX: RAP), Whitebark Energy (ASX: WBE) and Knosys (ASX: KNO) Webinar Recap – RAP, WBE & KNOCompany News

ShareCafeResApp (ASX: RAP) – Webinar Presentation Tony Keating – CEO & Managing Director – ResApp is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease. More ResApp...

Pressure put on global economies since the war in Ukraine started a root cause of inflation Vanguard analysis shows investors who stay the course instead of cashing out during volatility are rewarded Energy stocks an inflation hedge over t...

The S&P/ASX 200 Health Care Index (ASX: XHJ) is in the red today, but this one ASX share is bucking the trend. The ResApp Health Ltd (ASX: RAP) share price is currently at 17 cents, a 3.03% gain. It comes despite the ASX 200 healthca...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another decline. At the time of writing, the benchmark index is down 0.4% to 6,660.3 points. Four ASX shares that are not letting that hold them back are lis...

Global pharmaceutical giant Pfizer has almost doubled its initial offer for digital healthcare business ResApp Health (ASX: RAP) to roughly $180 million, after an independent expert found the original April price significantly undervalued t...

Sydney. Tuesday 14th. 12.34pm. Just as Bridge Street ran slick and red with the blood of investors, fundies, crypto-ingénues, CEOs and their caps – both small and large from sectors across every corner of the market – something strange and...

Benchmark collapses Small caps down 6% Hamelin brings hope   After a really terrific Queen’s Birthday long weekend, local markets already had a session of losses to catch up on at the open. Needless to say, they have. The benchmark took...

The ResApp Health Ltd (ASX: RAP) share price is by far one of the best performers on the ASX today. This comes as the company provided an update on its proposed acquisition by Pfizer Inc (NYSE: PFE), with trading resuming immediately after...

Pfizer bolsters its takeover bid for WA-founded ResApp Health (RAP) after an independent expert report found ResApp’s current share price was undervalued The pharmaceutical giant is now offering either 20.7 cents or 14.6 cents per RAP shar...